MedWatch

A part of Watch Media

Demant breaks off all trading with Russia after GN boycott, WSA says supplying Russia "impossible"

Hearing aid manufacturer Demant has chosen to suspend all trade with Russia, in addition to Ukrainian regions Donetsk and Luhansk. WS Audiology says trading with Russia is ”de facto impossible” due to airspace restrictions, why the company has also halted sales.

Photo: Demant / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

It is not only hearing aid group GN Store Nord that has decided to suspend all trading with Russia following its invasion of Ukraine.

The company competitor Demant, the world’s second-biggest hearing aid manufacturer, now joins the ranks, the company’s vice president of corporate communication, Trine Kromann-Mikkelsen, tells MedWatch.

”Based on sanctions coming into force from yesterday (Tuesday, ed.), we have now halted trades with Russia, Belarus and the regions in Ukraine, Donetsk and Luhansk,” she writes in an email.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Foto: Thomas Borberg/Politiken/Ritzau Scanpix

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

  1. Top news from MedWatch this week
  2. Extra data boosts Lundbeck's agitation case
  3. Acquisitions to help Coloplast attain growth goal
  4. Coloplast conducts catheter study to highlight single-use benefits
  5. FDA confirms rejection of Y-mabs' cancer drug
  6. Novo reaches share milestone, analyst credits Wegovy
  7. FDA approves Ferring microbiotica-based treatment
  8. Analyst spies alternative buyers in the wings as Cochlear's potential Oticon acquisition raises eyebrows
  9. Analyst proposes four solutions as GN battles with ghosts of debts past
  10. Former US head of Leo Pharma gets board seat at Kempharm
  11. Novo Nordisk to test best-selling substance in stroke indication
  12. ALK CFO to step down
  13. Potential Demant divestment raises competition concerns
  14. Pharmacosmos tight-lipped on competitor's Chinese market nod
  15. UK authority warns of Dupixent adverse effects

See all

Job

See all jobs

See all jobs